Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Labour Court says SIPTU should be recognised to represent Eli Lilly workers in Cork amid a growing industrial standoff ...